abstract |
A combination comprising a therapeutically effective amount of an aldosterone receptor epoxy-steroidal antagonist, a therapeutically effective amount of a diuretic that is not an aldosterone receptor antagonist type and a therapeutically effective amount of an angiotensin converting enzyme inhibitor, wherein said angiotensin-converting enzyme inhibitor is selected from the group consisting of alacepril, benazepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopil, quinapril, ramipril, traprol, sapphire , ceranapril, moexipril, quinaprilat, spirapril, Bioproject BP1.137, Chiesi CHF 1514, Fisons FPL-66564, idrapril, Marion Merrell Dow MDL-100240, perindoprilat, and Servier S-5590. |